Latest Pharma and Biotech News
Biotechnology
28 November 2024 Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma.
Today's issue
Refine Search
Biotechnology
Continuing its progress in addressing different cancer types across different geographies, immuno-oncology blockbuster Tecentriq (atezolizumab) has secured Chinese approval in extensive-stage small cell lung cancer (ES-SCLC). 14 February 2020
Biotechnology
Johnson & Johnson’s pharma arm, Janssen, has announced interim data from the Phase IIIb STARDUST study of Stelara (ustekinumab). 14 February 2020
Biotechnology
As high drug prices continue to incite public outcry and US legislation, it is nonetheless possible that Regeneron Pharmaceuticals’ (Nasdaq: REGN) drug for a rare cholesterol condition could lock in as much as $500,000 annually. 14 February 2020
Biotechnology
US clinical-stage synthetic biology company Codagenix has entered into a collaboration with the Serum Institute of India to rapidly co-develop a live-attenuated vaccine against the emergent coronavirus. 13 February 2020
Biotechnology
US pharma major Bristol-Myers Squibb today announced that the US Food and Drug Administration has accepted for Priority Review its Biologics License Application (BLA) for lisocabtagene maraleucel (liso-cel). 13 February 2020
Biotechnology
Tumor drug resistance specialist Deciphera Pharmaceuticals yesterday revealed that the US Food and Drug Administration has accepted for priority review its New Drug Application (NDA) seeking approval for ripretinib. 13 February 2020
Biotechnology
Nordic biotech firm Swedish Orphan Biovitrum today announced its results for the fourth quarter and full-year 2019. Revenue growth for the full-year was 56% with sales of 14,248 million Swedish kronor ($1.48 billion). 13 February 2020
Biotechnology
In early morning trading on Thursday, shares in Paris-based drugmaker Ipsen slumped nearly 6% following a results statement showing revenues of 2.57 billion euros ($2.8 billion) for full-year 2019, a little under the FT’s consensus estimate. 13 February 2020
Biotechnology
Shares in US biotech CytoDon were 7% up after Wednesday morning's trading following news of a development and licensing deal for leronlimab in China. 13 February 2020
Biotechnology
Irish immuno-oncology specialist ALX Oncology has raised $105 million in a series C equity financing, led by Vivo Capital. 12 February 2020
Biotechnology
ElevateBio portfolio company AlloVir revealed today that the European Medicines Agency has granted PRIority MEdicines (PRIME) designation to Viralym-M (ALVR105). 12 February 2020
Biotechnology
The psoriatic arthritis (PsA) market was valued at $4.7 billion in 2018 across the seven major markets (7MM: USA, France, Germany, Italy, Spain, UK and Japan), and it is expected to grow to $9.2 billion by 2028 at a compound annual growth rate (CAGR) of 6.9%. 12 February 2020
Biotechnology
Cassava Sciences, a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that The Journal of Prevention of Alzheimer’s Disease (JPAD), a peer-reviewed journal for the research community, published results from the company’s Phase IIa study demonstrating that its lead drug candidate, PTI-125, reduced biomarkers of disease in Alzheimer’s patients. 11 February 2020
Biotechnology
Every drug developer with ambitions to be part of the precision medicine revolution knows that improved detection rates are key to treating diseases earlier and more effectively. 11 February 2020
Biotechnology
Danish diabetes care giant Novo Nordisk has launched Esperoct (turoctocog alfa pegol) for people with hemophilia A in the USA. 11 February 2020
Biotechnology
Gilead Sciences subsidiary Kite on Tuesday announced that the US Food and Drug Administration has accepted the Biologics License Application (BLA) and granted Priority Review designation for KTE-X19, an investigational chimeric antigen receptor (CAR) T cell therapy for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL). 11 February 2020
Biotechnology
Shares in CNS specialist Biohaven Pharmaceutical were 8% down after an hour of trading on Monday. 10 February 2020
Biotechnology
Shares in US biotech Moderna closed 17% higher on Friday. 10 February 2020
Biotechnology
Eli Lilly’s hopes that coming up with a new trial design might mean a different result for its Alzheimer’s candidate, solanezumab, have been dashed. 10 February 2020
Biotechnology
USA-based medical technology firm Valeritas Holdings has reached agreement to sell substantially all of the business to Danish biotech Zealand Pharma. 10 February 2020
All news
Biotechnology
Zug-based Galderma has published positive results from the Phase III OLYMPIA 1 trial in JAMA Dermatology, as the company’s newly-minted shares change hands in record volumes. 29 November 2024
Biotechnology
Indian drugmaker Dr Reddy’s Laboratories has launched its toripalimab in the domestic market, sending the firm’s share up 2%. Toripalimab is a New Biological Entity (NBE), the company noted. 29 November 2024
Biotechnology
French pharma major Sanofi has added a new plant in Singapore to make vaccines and other medicines, as the company seeks to bolster preparedness for emergencies, including potential pandemics, according to Bloomberg and other media reports. 29 November 2024
Biotechnology
During the Belgian Economic Mission to Brazil, a historic Memorandum of Understanding (MoU) was signed between the Brazilian Oswaldo Cruz Foundation (Fiocruz) through its Institute of Technology on Immunobiologicals (Bio-Manguinhos), and the Belgian companies Quantoom Biosciences and Univercells. 29 November 2024
Biotechnology
PTC Therapeutics is to sell its rare pediatric disease priority review voucher (PRV) for $150 million. 28 November 2024
Biotechnology
A report from industry analyst DelveInsight highlights progress in the myotonic dystrophy treatment landscape, with more than 20 companies developing over 22 innovative treatments. 28 November 2024
Biotechnology
The UK subsidiary of Dutch drugmaker argenx confirmed today that its investigational therapy, subcutaneous efgartigimod alfa has been granted Promising Innovative Medicine (PIM) designation by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP). 28 November 2024
Biotechnology
Privately-held French drugmaker Servier has announced the inauguration of its first unit dedicated to the production of biological medicines from its R&D pipeline. 28 November 2024
Biotechnology
The US Food and Drug Administration has received new reports of hematologic malignancies, including life-threatening cases of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), following treatment of early, active cerebral adrenoleukodystrophy (CALD) patients with Skysona (elivaldogene autotemcel). 28 November 2024
Biotechnology
San Diago, USA-based Acadia Pharmaceuticals yesterday announced it has entered into an exclusive worldwide license agreement with Denmark’s Saniona for the development and commercialization of SAN711, a first-in-class, highly selective GABAA-α3 positive allosteric modulator. 28 November 2024
Biotechnology
Kronos Bio, a biotech with a presence on the east and west coasts of the USA, has unveiled a major restructuring plan. 28 November 2024
Biotechnology
Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma. 28 November 2024
Biotechnology
The European medicines regulator has approved a combo therapy starring PD-1 inhibitor Tevimbra (tislelizumab), from cancer firm BeOne Medicines, formerly BeiGene. 27 November 2024
Biotechnology
After trading closed yesterday, Exelixis revealed that the US Food and Drug Administration (FDA) has notified the company that the supplemental New Drug Application (sNDA) for cabozantinib (Cabometyx) for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic NET (epNET) will be discussed at an Oncologic Drugs Advisory Committee (ODAC) meeting in March 2025. 27 November 2024
Biotechnology
Chengdu-based Kelun-Biotech has received marketing authorization in China for sacituzumab tirumotecan (sac-TMT), a Trop2-directed antibody-drug conjugate (ADC). 27 November 2024
Biotechnology
AI-powered protein engineering company Cradle has raised $73 million in a Series B funding. The European firm, which has now raised more than $100 million in total, calls itself the leading platform for AI-powered protein engineering. 27 November 2024
Biotechnology
US clinical stage biotech Alector saw its shares tumble 35% to $2.57 by close of trading yesterday, as it announced disappointing results from the INVOKE-2 Phase II clinical trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer’s disease (AD). 27 November 2024
Biotechnology
PTC Therapeutics has announced that its Phase II trial for utreloxastat, aimed at treating amyotrophic lateral sclerosis (ALS), failed to meet its primary endpoint. 27 November 2024
Biotechnology
US companies Arrowhead Pharmaceuticals and Sarepta Therapeutics have announced a global licensing and collaboration agreement. 26 November 2024
Biotechnology
Clinical-stage US CAR-T therapies developer Poseida Therapeutics saw its shares skyrocket 227% to $9.36 pre-market today, on the news of a proposed takeover by Swiss pharma giant Roche. 26 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze